LivaNova PLC Files 8-K with Regulatory Updates

Ticker: LIVN · Form: 8-K · Filed: 2024-11-01T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, corporate-information

TL;DR

LivaNova PLC filed an 8-K on Nov 1, 2024, covering regulatory disclosures and financial statements.

AI Summary

LivaNova PLC filed an 8-K on November 1, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's principal executive offices in London, United Kingdom, and its fiscal year end of December 31. It also notes previous name changes from Sand Holdco Plc and Sand Holdco Ltd.

Why It Matters

This filing provides essential corporate and financial information for LivaNova PLC, crucial for investors and stakeholders to stay informed about the company's status and reporting requirements.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any significant new risks or material adverse information.

Key Numbers

Key Players & Entities

FAQ

What specific items are covered under the Regulation FD Disclosure?

The provided text does not specify the details of the Regulation FD Disclosure, only that it is an item reported in the 8-K.

What are the primary business activities of LivaNova PLC?

The filing lists LivaNova PLC under Standard Industrial Classification 3845, which is ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS, but does not elaborate on specific business activities.

When did LivaNova PLC change its name from Sand Holdco Plc?

The filing indicates the date of name change from Sand Holdco Plc was April 20, 2015.

What is the fiscal year end for LivaNova PLC?

The fiscal year end for LivaNova PLC is December 31.

What is the physical address of LivaNova PLC's principal executive offices?

The principal executive offices are located at 20 Eastbourne Terrace, London, W2 6LG, United Kingdom.

From the Filing

0001639691-24-000139.txt : 20241101 0001639691-24-000139.hdr.sgml : 20241101 20241101171222 ACCESSION NUMBER: 0001639691-24-000139 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241101 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241101 DATE AS OF CHANGE: 20241101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LivaNova PLC CENTRAL INDEX KEY: 0001639691 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 981268150 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37599 FILM NUMBER: 241419978 BUSINESS ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG BUSINESS PHONE: 4402033250662 MAIL ADDRESS: STREET 1: 20 EASTBOURNE TERRACE CITY: LONDON STATE: X0 ZIP: W2 6LG FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Plc DATE OF NAME CHANGE: 20150420 FORMER COMPANY: FORMER CONFORMED NAME: Sand Holdco Ltd DATE OF NAME CHANGE: 20150415 8-K 1 livn-20241101.htm 8-K livn-20241101 LIVANOVA PLC 0001639691 false 0001639691 2024-11-01 2024-11-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2024 LivaNova PLC (Exact Name of Registrant as Specified in its Charter) England and Wales 001-37599 98-1268150 (State or Other Jurisdiction  of Incorporation) (Commission File Number) (IRS Employer Identification No.) 20 Eastbourne Terrace London , W2 6LG United Kingdom (Address of Principal Executive Offices) + 44 20 33250660 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name on each exchange on which registered Ordinary Shares - £1.00 par value per share LIVN NASDAQ Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure. On November 1, 2024, the U.S. Centers for Medicare and Medicaid Services (CMS) announced that it is maintaining VNS Therapy™ for drug-resistant epilepsy (DRE) at the Level 5 Neurostimulator and Related Procedures Ambulatory Payment Classification (APC) under the 2025 Medicare Hospital Outpatient Prospective Payment System. While the Company is disappointed by this decision, it does not believe that this decision will impact the business. LivaNova will continue to pursue reimbursement opportunities for VNS Therapy for DRE. Item 9.01 Financial Statements and Exhibits (d)    Exhibits. Exhib

View on Read The Filing